SMA Pipeline: H2 2016 Spinal Muscular Atrophy Therapeutics Market Review

PUNE, India, September 13, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016" market research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects.

Complete report on H2 2016 pipeline review of Spinal Muscular Atrophy (SMA) with 33 market data tables and 15 figures, spread across 116 pages is available at http://www.rnrmarketresearch.com/spinal-muscular-atrophy-sma-pipeline-review-h2-2016-market-report.html .

Spinal Muscular Atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.

Spinal Muscular Atrophy (SMA) pipeline therapeutics constitutes close to 30 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Companies discussed in this Spinal Muscular Atrophy (SMA) Pipeline Review, H2 2016 report include Astellas Pharma Inc., AveXis, Inc., Bio Blast Pharma Ltd., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, Ionis Pharmaceuticals, Inc., Neurodyn Inc., Neurotune AG, Novartis AG, Paratek Pharmaceuticals, Inc., RaNA Therapeutics, Inc., Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc. and WAVE Life Sciences Ltd.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=688263 .

Drug Profiles mentioned in this research report are AAD-2004, ALB-111, Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy (SMA), Antisense Oligonucleotides for Spinal Muscular Atrophy (SMA), AVXS-101, azithromycin, CK-2127107, Gene Therapy to Activate SMN for Spinal Muscular Atrophy (SMA), Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy (SMA), LMI-070, ND-602, NT-1654, nusinersen, olesoxime, Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy (SMA), Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy (SMA), PMO-25, PTKSMA-1, RG-7800, RG-7916, Small Molecules for Central Nervous System Disorders, Small Molecules for Spinal Muscular Atrophy (SMA), Small Molecules to Activate SMN2 for Spinal Muscular Atrophy (SMA), Small Molecules to Activate SMN2 for Spinal Muscular Atrophy (SMA), Small Molecules to Activate Survival Motor Neuron Protein for Spinal Muscular Atrophy (SMA), Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders, Small Molecules to Inhibit GSK-3 for Spinal Muscular Atrophy (SMA), tirasemtiv and VYSMN-101.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Another newly published market research report titled on Atrial Fibrillation - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are ARCA biopharma, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Cardiome Pharma Corp., Daiichi Sankyo Company, Limited, Dong-A Socio Holdings Co. Ltd., Gilead Sciences, Inc., Laboratoires Pierre Fabre SA, Nissan Chemical Industries, Ltd., OMEICOS Therapeutics GmbH, Otsuka Holdings Co., Ltd. and Xention Limited. Atrial Fibrillation Pipeline market research report of 97 pages is available at http://www.rnrmarketresearch.com/atrial-fibrillation-pipeline-review-h2-2016-market-report.html .

Explore more reports on Therapeutics .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed